Sera Prognostics (SERA) Stock Price, News & Analysis

Company Overview

Sera Prognostics, Inc. is a molecular diagnostics company headquartered in Salt Lake City, Utah, focused on transforming prenatal care through advanced predictive testing. Founded in 2014 as a spin-out from Stanford University research, the company leverages proprietary proteomic and bioinformatic technologies to identify biomarkers associated with preterm birth. Under the leadership of CEO Glynis A. Darnell and a management team with extensive experience in biotechnology and women’s health, Sera Prognostics aims to improve clinical outcomes for expectant mothers and infants.

The company’s flagship offering is the PreTRM® test, a blood-based assay designed to assess a pregnant individual’s risk of spontaneous preterm birth between 19 and 20 weeks of gestation. By measuring the ratio of two key proteins in maternal serum, PreTRM® provides clinicians with an early risk stratification tool, enabling timely intervention strategies such as specialized monitoring, lifestyle counseling or prophylactic therapies. Sera Prognostics continues to expand its pipeline of pregnancy-related diagnostics, exploring additional biomarkers for conditions like preeclampsia and other adverse maternal-fetal outcomes.

To date, Sera Prognostics has established collaborations with leading academic institutions, contract research organizations and healthcare providers across the United States. The company participates in clinical trials and validation studies to support regulatory submissions and broaden adoption in obstetric practice. While operations remain focused on North America, Sera Prognostics is exploring partnerships to extend access to its diagnostics in Europe, Asia and other global markets where preterm birth poses a significant public health challenge.

Since its inception, Sera Prognostics has secured funding through private placements and initial public offerings, positioning the company for continued growth in women’s health diagnostics. Its scientific advisory board comprises experts in maternal-fetal medicine, proteomics and obstetric epidemiology, ensuring that the company’s research and development efforts remain at the forefront of prenatal risk assessment. As the burden of preterm birth continues to rise globally, Sera Prognostics is poised to deliver innovative tools that empower clinicians and expectant families with actionable insights early in pregnancy.

Key Stats

• Today's Range: $2.37 to $2.49
• 50-Day Range: $1.49 to $4.09
• 52-Week Range: $1.37 to $9.13
• Volume: 80,123 shs
• Average Volume: 178,121 shs
• Market Capitalization: $91.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Sera Prognostics Stock Analysis - MarketRank™

Sera Prognostics scored higher than 27% of companies evaluated by MarketBeat, and ranked 794th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sera Prognostics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Sera Prognostics are expected to decrease in the coming year, from ($0.96) to ($0.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sera Prognostics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sera Prognostics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sera Prognostics has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.75% of the float of Sera Prognostics has been sold short.

Short Interest Ratio / Days to Cover

Sera Prognostics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Sera Prognostics has recently decreased by 13.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sera Prognostics does not currently pay a dividend.

Dividend Growth

Sera Prognostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.75% of the float of Sera Prognostics has been sold short.

Short Interest Ratio / Days to Cover

Sera Prognostics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Sera Prognostics has recently decreased by 13.39%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.72

News Sentiment

Sera Prognostics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Sera Prognostics this week, compared to 1 article on an average week.

Search Interest

4 people have searched for SERA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,856.00 in company stock.

Percentage Held by Insiders

15.80% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SERA Stock Analysis - Frequently Asked Questions

How have SERA shares performed this year?

Sera Prognostics' stock was trading at $8.14 at the beginning of the year. Since then, SERA stock has decreased by 69.3% and is now trading at $2.4950.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. The business earned $0.04 million during the quarter, compared to analyst estimates of $0.06 million. Sera Prognostics had a negative net margin of 28,685.22% and a negative trailing twelve-month return on equity of 51.35%.
Read the conference call transcript.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share.

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sera Prognostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sera Prognostics investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:SERA
• CIK: 1534969
• Web: www.seraprognostics.com
• Phone: 801-990-0520
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.90 million
• Net Margins: -28,685.22%
• Pretax Margin: -28,685.22%
• Return on Equity: -51.35%
• Return on Assets: -37.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.02
• Quick Ratio: 2.02

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 1,174.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.40 per share
• Price / Book: 1.78

Miscellaneous

• Outstanding Shares: 37,670,000
• Free Float: 31,721,000
• Market Cap: $93.99 million
• Optionable: Optionable
• Beta: 0.99